Hedge funds cut NFLX, keep big bets on MSFT, AMZN, add NVDA
NASHVILLE, TN—Kenneth Krogulski, a director at Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), has recently increased his stake in the company, a move that aligns with the stock’s impressive 337% surge over the past six months. According to a series of transactions disclosed in a recent SEC filing, Krogulski acquired shares of Cumberland Pharmaceuticals over the course of May 2025. The company, currently valued at $80.79 million, maintains a GOOD financial health score according to InvestingPro analysis.
The transactions, executed under a Rule 10b5-1 trading plan, saw Krogulski purchase a total of 990 shares of common stock. The purchases were made at prices ranging from $4.50 to $5.68 per share, amounting to a total value of $4,824. The stock, which tends to move independently from the broader market with a beta of -0.29, is currently trading at $5.40 per share. InvestingPro subscribers can access 8 additional key insights and a comprehensive Pro Research Report about Cumberland Pharmaceuticals.
These acquisitions highlight Krogulski’s continued confidence in the company’s prospects, which has shown strong momentum with an 8.87% gain in the past week alone. Following these transactions, Krogulski’s direct ownership of Cumberland Pharmaceuticals’ common stock increased to 285,698 shares.
In other recent news, Cumberland Pharmaceuticals reported a strong performance in the first quarter of 2025, with net revenue reaching $11.7 million, reflecting a 38% increase from the previous year. The company also posted adjusted earnings per share of $0.16. This revenue growth was driven by the approval of Vibativ in China and expanded Medicaid coverage for Cristalose, highlighting Cumberland’s expanding market presence. Additionally, Cumberland Pharmaceuticals unveiled promising study results for Caldolor, which demonstrated a 23% reduction in morphine use among patients aged 60 and above, suggesting potential benefits in pain management for seniors.
The study also showed that Caldolor led to a reduction in pain both at rest and with movement after surgery, with no significant increase in adverse events. Cumberland’s CEO, A.J. Kazimi, emphasized the company’s commitment to improving pain management for diverse patient demographics, particularly in light of the aging global population. Furthermore, the company remains optimistic about the future, with ongoing clinical trials for its ifetroban product candidate and the potential for targeted acquisitions to bolster its market position. Analyst firms have not recently upgraded or downgraded the stock, but the company’s strategic developments indicate a focus on innovation and growth.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.